Document is current

Article History

Received: 4 December 2020

Accepted: 9 April 2021

First Online: 16 June 2021

Declarations

:

: Mitchell Levy, Simon Finfer, Flavia Machado, Lewis Kaplan, Jozef Kesecioglu, Ron Daniels, Niranjan Kissoon, Emmanuel Nsutebu, Imrana Malik, Abdulelah Alhawsawi, Greg Martin, and Luregn Schlapbach declare that they have no competing interests. Gorordo-Delsol AL - LAG-D reports personal fees from Pfizer de México SA de CV, personal fees from Merck Sharp & Dohme S de RL de CV, personal fees from Abbott Laboratories de México SA de CV, all outside the submitted work; Global Sepsis Alliance Executive Committee Member. Evangelos Giamarellos-Bourboulis - has received honoraria from Abbott CH, Angelini Italy, InflaRx GmbH, MSD Greece, XBiotech Inc., and B·R·A·H·M·S GmbH (Thermo Fisher Scientific); independent educational grants from AbbVie Inc, Abbott CH, Astellas Pharma Europe, AxisShield, bioMérieux Inc, Novartis, InflaRx GmbH, and XBiotech Inc; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis). Maurizio Cecconi – Member of surviving sepsis campaign executive committee, ESICM President Elect (may be President when this is accepted), panel member WHO Guidance on Drugs for COVID19, consulting fees for Edwards Lifesciences and Directed Systems Konrad Reinhart – Was unpaid President of the Global Sepsis Alliance until November 2012 and is shareholder of InflaRx NV a Jena/Germany based Biotech Company that evaluates an immune-modulatory approach for the adjunctive treatment of COVID-19. Andrew Rhodes – Co-chair of the Surviving Sepsis Campaign (SSC).